Fempro 2.5 mg

Fempro 2.5 mg is a hormonal anti-cancer medicine containing letrozole 2.5 mg. It is used in the management of certain estrogen receptor-positive breast cancers particularly in women after menopause.
Fempro lowers estrogen production by inhibiting aromatase. This may help to limit the hormone related stimulation of breast cancer cells that rely on estrogen for growth.

Key Features

How does Fempro 2.5 mg work?

Fempro 2.5 mg works by blocking aromatase an enzyme involved in making estrogen. After menopause esstrogen is mainly produced through this conversion process in body tissue rather than directly by the ovaries.
As estrogen levels fall, estrogen-dependent breast cancer cells may receive less hormonal stimulation. This can help slow their growth as part of the overall cancer treatment approach.

Usage

Take Fempro 2.5 mg exactly as prescribed, usually with a glass of water. It can generally be taken with or without food. Continue treatment regularly unless the oncologist tells you to stop or change the medicine.

Dosage 

The usual dose is one Fempro 2.5 mg tablet once daily. The treating oncologist will determine the appropriate duration based on the condition being treated, previous therapies, tolerance and follow-up findings.

Side effects

Fempro 2.5 mg can cause side effects although not everyone experiences them. Commonly reported effects include:

• Hot flushes
• Joint or bone pain
• Muscle aches
• Tiredness
• Headache
• Dizziness
• Nausea
• Ankle or hand swelling
• Increased cholesterol
• Bone loss with longer-term use

Seek urgent medical guidance for signs of a serious allergic reaction, chest pain, sudden breathing problems or symptoms that are severe or unusual.

Interactions

Major Drug Interactions

• Estrogens – Estrogen-containing medications completely counteract the medical purpose of letrozole. Avoid using hormonal contraceptives, hormone replacement therapy (HRT), or estrogen creams. 
• Tamoxifen – Co-administration can significantly lower the blood concentration of letrozole reducing its clinical effectiveness. 
• CYP2C19 Liver Enzyme Inhibitors – Letrozole is an inhibitor of the CYP2C19 liver enzyme. May increase blood levels and toxicity risk of drugs metabolized by this pathway eg, clopidogrel, citalopram.

Food & Lifestyle Interactions

• Alcohol – Some side effects such as dizziness, tiredness and flushing may occur if you take this medicine with alcohol.
  Grapefruit – Avoid grapefruit and grapefruit juice while taking this medication. It can affect the way the liver metabolizes the drug.

Pharmacokinetics

Fempro 2.5 mg is an oral tablet containing the active substance letrozole a potent nonsteroidal aromatase inhibitor.

• Bioavailability – The absolute bioavailability of letrozole is 99.9%, indicating complete absorption from the gastrointestinal tract.
• Protein Binding – Letrozole is moderately bound to plasma proteins (approximately 60%), primarily to albumin
• Enzymes Involved – Metabolism is primarily mediated by CYP3A4 and CYP2A6.
• Half-life – Terminal elimination half-life of about 2 days (range 36 to 48 hours). It may take up to 10 to 14 days for full washout from the system.
• Excretion – Roughly 90% of a radiolabeled dose is recovered in the urine, primarily as the glucuronide conjugate of the inactive metabolite. Less than 4% is excreted as an unchanged drug. 

Precautions

Fempro should only be used under specialist medical supervision.

• Do not use during pregnancy
• Discuss contraception with the doctor if pregnancy is possible
• Breastfeeding should be avoided during therapy and for at least three weeks after the last dose
• Bone health assessment may be necessary, particularly with long-term treatment
• Inform the doctor about osteoporosis, fractures, liver disease or high cholesterol
• Use caution with driving if the medicine causes tiredness or dizziness

Conclusion

Fempro 2.5 mg contains letrozole and is prescribed for certain estrogen-sensitive breast cancers in postmenopausal women. It helps lower estrogen levels and should be used according to an oncologist’s treatment plan. Regular monitoring can help identify bone, cholesterol, liver and tolerability-related concerns early.

FAQs